2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
87
Leukemia
49
Lymphoma
21
Burkitt Lymphoma
19
Leukemia, Biphenotypic, Acute
14
Leukemia, Myeloid, Acute
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, Extranodal NK-T-Cell
8
Recurrence
6
Lymphoma, Non-Hodgkin
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Myelodysplastic Syndromes
4
Dendritic Cell Sarcoma, Interdigitating
4
Neoplasm, Residual
3
Down Syndrome
3
Anemia, Refractory, with Excess of Blasts
3
Myeloproliferative Disorders
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Monocytic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Eosinophilic, Acute
2
Anemia, Refractory
2
Thrombocytopenia
1
Sarcoma, Myeloid
1
Pancreatic Neoplasms
1
Neutropenia
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
98
Fluorouracil
90
Capecitabine
86
Dexamethasone
81
Radiotherapy
80
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Leucovorin
64
Drug Therapy
64
Cetuximab
60
Erlotinib Hydrochloride
56
Sorafenib
53
atezolizumab
52
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Asparaginase
×
Clear all
NCT03665441
2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3
Completed
512 enrolled
19 charts